Clinical Trials
Braintumor Website

 For People with Newly Diagnosed Glioblastoma Multiforme
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM)
With Epidermal Growth Factor Receptor (EGFR) Amplification

 For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
A Study of ABT-414 in Adult or Pediatric Subjects With Recurrent Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Aldoxorubicin Trial for recurrent GBM.

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT03058289

  A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
304/06/2017

NCT02851706

  Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
104/06/2017

NCT02455557

  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
504/06/2017

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
704/06/2017

NCT01502917

  Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
104/06/2017

NCT01326104

  Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
304/06/2017

NCT02617589

  An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
12104/05/2017

NCT02520882

  68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas
104/05/2017

NCT01801371

  68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
104/05/2017

NCT01356290

  Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
1204/05/2017

NCT02992964

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
104/04/2017

NCT02945826

  uPAR-PET/MRI in Glioblastoma Multiforme
104/04/2017

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
1904/04/2017

NCT02764151

  First in Patient Study for PF-06840003 in Malignant Gliomas
1504/04/2017

NCT02667587

  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
11804/04/2017

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
6404/04/2017

NCT02311920

  Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
1004/04/2017

NCT02308020

  A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
4904/04/2017

NCT02271711

  Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors
104/04/2017

NCT02142803

  TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
204/04/2017

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
1904/04/2017

NCT01849146

  WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
404/04/2017

NCT01770353

  Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
404/04/2017

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
10304/04/2017

NCT03075514

  Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
104/03/2017

NCT03033706

  Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy
104/03/2017

NCT02971319

  Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma
904/03/2017

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
2404/03/2017

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
204/03/2017

NCT02359565

  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors
304/03/2017

NCT02255461

  Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
1104/03/2017

NCT02029690

  Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
104/03/2017

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
1304/03/2017

NCT02997423

  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
1803/31/2017

NCT01644773

  Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
103/31/2017

NCT00897286

  Study of Stored Tumor Samples in Young Patients With Brain Tumors
103/31/2017

NCT03102203

  Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
103/30/2017

NCT03101813

  International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository
103/30/2017

NCT02661282

  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients
103/30/2017

NCT02234050

  Trabectedin for Recurrent Grade II/III Meningioma
4703/30/2017

NCT02223052

  Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
903/30/2017

NCT01878617

  A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
1803/30/2017

NCT00602667

  Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
603/30/2017

NCT02864368

  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
103/29/2017

NCT02792582

  A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
103/29/2017

NCT02500459

  Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
103/29/2017

NCT02358187

  A Vaccine Trial for Low Grade Gliomas
103/29/2017

NCT02208362

  Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
103/29/2017

NCT01925573

  Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
103/29/2017

NCT01130077

  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
103/29/2017



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites